Silo Pharma files patent for ibogaine-based therapy targeting traumatic brain injury.

Silo Pharma has filed a provisional patent for a new ibogaine-based treatment aimed at traumatic brain injury (TBI) and related neuropsychiatric conditions like PTSD. This initiative aligns with recent clinical findings showing ibogaine's potential to improve brain structure and reduce symptoms such as depression and anxiety in TBI patients. With no FDA-approved drugs currently addressing the structural damage from TBI, Silo's approach could represent a major advancement in neurotherapeutics. The global market for TBI treatments is expected to reach $6 billion by 2032, highlighting significant growth potential for innovative therapies like Silo's.